Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study

Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study

(2011) J. W. Nin et al.   DIABETES CARE

Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study

(2011) Johanna W M Nin et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure

(2011) Ling Jie Wang et al.   EUROPEAN JOURNAL OF HEART FAILURE

HMGB1 and RAGE in Inflammation and Cancer

(2010) Gary P. Sims et al.   Annual Review of Immunology

High-Mobility Group Box Protein 1 Neutralization Reduces Development of Diet-Induced Atherosclerosis in Apolipoprotein E–Deficient Mice

(2010) Peter Kanellakis et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Increased serum HMGB1 is related to the severity of coronary artery stenosis

(2009) Xiaorong Hu et al.   CLINICA CHIMICA ACTA

Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients

(2008) Xiao Xiang Yan et al.   ATHEROSCLEROSIS